bluebird bio Announces Proposed Public Offering of Common Stock
December 11 2017 - 4:01PM
Business Wire
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage
biotechnology company committed to developing potentially
transformative gene therapies for severe genetic diseases and
cancer, today announced that it has commenced an underwritten
public offering of $600 million of its common stock. bluebird bio
also intends to grant the underwriters a 30-day option to purchase
up to an additional fifteen percent (15%) of the shares of
common stock offered in the public offering. All of the shares in
the proposed offering are to be sold by bluebird bio.
Goldman Sachs & Co. LLC, BofA Merrill Lynch, J.P.
Morgan Securities LLC and Cowen are acting as joint book-running
managers of the proposed offering. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
The shares are being offered by bluebird bio pursuant to an
automatically effective shelf registration statement that was
previously filed with the Securities and Exchange Commission (SEC).
A preliminary prospectus supplement relating to and describing the
terms of the offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. When available,
copies of the preliminary prospectus supplement and the
accompanying prospectus relating to these securities may also be
obtained by contacting one of the following: Goldman
Sachs & Co. LLC, Attn: Prospectus Department, 200 West
Street, New York, NY 10282, telephone: (212) 902-1171,
facsimile: (212) 902-9316, email:
prospectus-ny@ny.email.gs.com; BofA Merrill Lynch, NC1-004-03-43,
200 North College Street, 3rd floor, Charlotte, NC 28255-0001,
Attn: Prospectus Department, email:
dg.prospectus_requests@baml.com; J.P. Morgan Securities LLC, c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (866) 803-9204 or Cowen and Company,
LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue,
Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at
(631) 274-2806 or by fax at (631) 254-7140. The final
terms of the offering will be disclosed in a final prospectus
supplement to be filed with the SEC.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of,
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to the registration or
qualification under the securities laws of such state or
jurisdiction.
About bluebird bio, Inc.With its lentiviral-based gene
therapies, T cell immunotherapy expertise and gene editing
capabilities, bluebird bio has built an integrated product platform
with broad potential application to severe genetic diseases and
cancer. bluebird bio's gene therapy clinical programs include its
Lenti-D™ product candidate, currently in a Phase 2/3 study, called
the Starbeam Study, for the treatment of cerebral
adrenoleukodystrophy, and its LentiGlobin® product candidate,
currently in five clinical studies for the treatment of
transfusion-dependent β-thalassemia, also known as β-thalassemia
major, and severe sickle cell disease. bluebird bio's oncology
pipeline is built upon the company's leadership in lentiviral gene
delivery and T cell engineering, with a focus on developing novel T
cell-based immunotherapies, including chimeric antigen receptor
(CAR T) and T cell receptor (TCR) therapies. bluebird bio's lead
oncology programs, bb2121 and bb21217, are anti-BCMA CAR T programs
partnered with Celgene. bb2121 and bb21217 are each currently
being studied in Phase 1 trials for the treatment of
relapsed/refractory multiple myeloma. bluebird bio also has
discovery research programs utilizing megaTALs/homing endonuclease
gene editing technologies with the potential for use across the
company's pipeline.
bluebird bio has operations in Cambridge, Massachusetts,
Seattle, Washington, Durham, North Carolina and Europe.
LentiGlobin and Lenti-D are trademarks of bluebird bio, Inc.
Forward-Looking Statements
This release contains “forward-looking statements” within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding the anticipated final terms, timing
and completion of the proposed offering, and bluebird bio’s
existing product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to, risks and uncertainties related to market
conditions and satisfaction of customary closing conditions related
to the proposed public offering, that the preliminary results from
our clinical trials will not continue or be repeated in our ongoing
clinical trials, the risk of cessation or delay of any of the
ongoing or planned clinical studies and/or our development of our
product candidates, the risk of a delay in the enrollment of
patients in our clinical studies, the risks that the changes we
have made in the LentiGlobin drug product manufacturing process or
the HGB-206 clinical study protocol will not result in improved
patient outcomes, risks that the current or planned clinical
studies of the LentiGlobin drug product will be insufficient to
support regulatory submissions or marketing approval in the United
States and European Union, risks that the current clinical study of
Lenti-D will be insufficient to support regulatory submissions or
marketing approval in the United States and European Union, the
risk that our collaborations, including the collaboration with
Celgene, will not continue or will not be successful, and the risk
that any one or more of our product candidates will not be
successfully developed, approved or commercialized. There can be no
assurance that bluebird bio will be able to complete the proposed
public offering on the anticipated terms, or at all. For a
discussion of other risks and uncertainties, and other important
factors, any of which could cause our actual results to differ from
those contained in the forward-looking statements, see the section
entitled “Risk Factors” in our annual report on Form 10-K and our
most recent quarterly report on Form 10-Q, as well as discussions
of potential risks, uncertainties, and other important factors in
our subsequent filings with the Securities and Exchange Commission.
All information in this press release is as of the date of the
release, and bluebird bio undertakes no duty to update this
information unless required by law.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171211006139/en/
Investor Relations and Mediabluebird bio, Inc.Elizabeth
Pingpank, 617-914-8736epingpank@bluebirdbio.com
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Aug 2024 to Sep 2024
bluebird bio (NASDAQ:BLUE)
Historical Stock Chart
From Sep 2023 to Sep 2024